Here are some of the stocks making notable moves in Monday's premarket action: Shares in Paramount Skydance rose almost 7% ...
Bajaj Finserv Ltd. closed 15.48% short of its 52-week high of 2,194.65 rupees, which the company achieved on October 23rd. Supported by world-class markets data from Dow Jones and FactSet, and ...
Larsen & Toubro Ltd. 500510 shares rose 1.20% to 3,906.50 Indian rupees Monday, on what proved to be an all-around positive trading session for the stock market, with the BSE SENSEX Index 1 rising ...
Sun Pharmaceutical Industries Ltd. 524715 +1.77% shares advanced 1.77% to 1,868.00 Indian rupees Monday, on what proved to be an all-around favorable trading session for the stock market, with the BSE ...
ITC Ltd. closed 37.34% below its 52-week high of 426.50 rupees, which the company reached on October 31st. Supported by world-class markets data from Dow Jones and FactSet, and partnering with ...
A team at the bank, led by Ben Snider, wrote in a recent note that they see S&P 500 earnings per share growth slowing to 11% ...
Current profit margins and strong balance sheets are expected by JPMorgan to continue to support equities in the U.S., Europe and Japan. Strategists at the investment bank, led by Mislav Matejka wrote ...
Brunswick Executive Chairman and Chief Executive David Foulkes is stepping down and will hand the separated roles to company insiders. The Illinois-based marine manufacturing company said Foulkes will ...
AtkinsRealis and partner Aecon landed a three-year, 1.7 billion Canadian dollars (US$1.2 billion) deal for the refurbishment of a unit at the Pickering nuclear power station in Ontario.
Dream Unlimited intends to renew its share-repurchase program to buy back up to 10% of its shares over the course of a one-year period. The Canadian real estate developer on Monday said that the ...
Constellation Energy's venture capital arm invested in a $7 million seed round for Fluxnium, a startup looking to commercialize domestic uranium sourced from seawater. The funding round was led by ...
Bayer agreed to sell rights to its cancer drug Stivarga to Gruenenthal Group for up to 375 million euros ($430.7 million), the acquirer said Monday. The drug, due to lose patent protection in the ...